Company Overview
Basel Medical Group Ltd provides healthcare services in Singapore. The company offers general and subspecialized orthopedic, including trauma and sports medicine services, such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery, and minimally invasive orthopedic procedures, as well as neurosurgical treatments. It also provides health screening services, mental health, woman's health, and general practice services. In addition, its services include consultation, medical diagnosis, and medical and surgical treatments. The company was incorporated in 2023 and is headquartered in Singapore.
Recent Developments
- Jun 2025 Revenue of $11.32M (+12.6% YoY); net profit $-10.64M.
- Trailing 12 Months Year-on-year growth — revenue +67.1%, earnings -613.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.0%, profit CAGR -212.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.03% |
| 1 Year: | 67.10% |
Compounded Profit Growth
| 5 Years: | -212.57% |
| 1 Year: | -613.11% |
Stock Price Performance
| 1 Year: | -77.88% |
| 6 Months: | -33.24% |
| 3 Months: | -23.12% |
| 1 Month: | -6.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.19 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -212.6% CAGR over 5 years.
- Trading 78.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BMGL Basel Medical Group Ltd | 5.60 | -0.97 | $8.77M | 0.00% | -127.36% | -147.37% | 2.03% | -212.57% |
| 2 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 3 | WAT Waters Corporation SPX | 400.00 | 50.96 | $39.27B | 0.00% | 20.92% | 5.21% | 4.60% | 2.80% |
| 4 | ZTS Zoetis Inc. SPX | 74.39 | 12.20 | $31.19B | 2.74% | 27.18% | 67.75% | 5.92% | 18.61% |
| 5 | ZBH Zimmer Biomet Holdings, Inc. SPX | 98.16 | 25.43 | $18.99B | 1.02% | 6.61% | 6.07% | 4.50% | -0.54% |
| 6 | BTSG BrightSpring Health Services, Inc. R2K | 59.71 | 77.55 | $11.72B | 0.00% | 6.47% | 9.23% | 18.69% | - |
| 7 | NUVL Nuvalent, Inc. R2K | 123.96 | -20.46 | $9.12B | 0.00% | -31.35% | -41.19% | - | - |
| 8 | IBRX ImmunityBio, Inc. R2K | 7.17 | -8.44 | $7.51B | 0.00% | -58.17% | 70.21% | 54.76% | - |
| 9 | BLTE Belite Bio, Inc | 158.50 | -62.16 | $6.35B | 0.00% | -10.07% | -18.93% | - | -171.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 10.66M | 9.70M | 10.05M | 11.32M |
| Cost of Revenue | 2.18M | 2.34M | 2.25M | 2.55M |
| Gross Profit | 8.48M | 7.36M | 7.80M | 8.77M |
| Operating Expenses | 6.01M | 5.29M | 5.61M | 10.94M |
| Operating Income | 2.47M | 2.07M | 2.20M | -2.18M |
| EBITDA | 3.28M | 2.93M | 3.11M | -9.67M |
| Interest Expense | 320.87K | 238.60K | 176.24K | 203.95K |
| Pretax Income | 2.39M | 2.13M | 2.40M | -11.05M |
| Tax Provision | 408.48K | 348.28K | 331.76K | -417.39K |
| Net Income | 1.98M | 1.78M | 2.07M | -10.64M |
| Diluted EPS | 0.12 | 0.10 | 0.11 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 16.85M | 15.38M | 16.31M | 18.68M |
| Current Assets | 15.67M | 14.77M | 16.17M | 13.29M |
| Cash & Equivalents | 1.56M | 1.22M | 1.95M | 3.04M |
| Inventory | 69.83K | 94.60K | 72.03K | 489.06K |
| Receivables | 2.01M | 1.44M | 1.67M | 2.15M |
| Total Liabilities | 13.14M | 9.89M | 8.75M | 13.24M |
| Current Liabilities | 7.19M | 6.47M | 7.16M | 10.16M |
| Long Term Debt | 5.31M | 3.40M | 1.58M | - |
| Total Debt | 10.15M | 7.21M | 4.29M | 5.08M |
| Total Equity | 3.71M | 5.49M | 7.56M | 5.43M |
| Shares Outstanding | 18.45M | 18.45M | 18.45M | 18.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 2.79M | 2.60M | 2.51M | -3.18M |
| Investing Cash Flow | -88.50K | -6.16K | -7.92K | -8.57M |
| Financing Cash Flow | -12.92M | -2.94M | -1.77M | 12.97M |
| Capital Expenditure | -88.50K | -6.16K | -7.92K | -437.88K |
| Free Cash Flow | 2.70M | 2.59M | 2.50M | -3.62M |
| Net Change in Cash | -10.22M | -346.24K | 733.61K | 1.22M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | 79.6% | 75.9% | 77.6% | 77.5% |
| Operating Margin % | 23.2% | 21.4% | 21.8% | -19.2% |
| Net Margin % | 18.6% | 18.4% | 20.6% | -94.0% |
| ROE % | 53.4% | 32.5% | 27.4% | -195.7% |
| ROCE % | 25.6% | 23.3% | 24.0% | -25.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BMGL
Basel Medical Group Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement | BMGL Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOWDl3YmFSdFRvOHFFZkc5RFRKTzQwa1FkRlNsSlhEekNraS05cVMxbUZxYTVORkZFQ0pqdUpOenVIRzJDT1lxVWlFRnZsTGxtYVJVTHUzRjRCWG1QX1U1ejFtaF9qODFVaXRPb3ZhYTRZYjltZ0Uxa0dFdHlKUm1kZXF4TFZ4eUd4bFlIan…
Why Did BMGL Stock Slump 18% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNazBlTmV4cFIwTEVJRjhsalBDbV8yd25hZ1cwZGhZTTQ0Q1NQblB3UXpKSERsVG50N3FBdkg4allUc0ozcWV0SVctdFRTZy10aFY4R19LdTVkclFwZmx1OTJIdWdoWFYzcDh2UFdNTW5kYzU1MHNSdHNJUWg2b2duQmlhM0h3NllqVXhvU3…
Basel Medical Group (BMGL) interim CFO files Form 3 with no insider trades - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPRGRMSFdYa25Pd1UybklLT1VJZDBGLUdOOGtBd2E2dWJqaFUtY25XM1RWaXZURGtmUWdreThWaUlqYThiV09MNUtKV0YwRmZmUjdXdWl6X2tULU54WW8tclZBbHc5cEp4Y2N0d1dtejloVEZUY0pyS20yak9KQU5Ianp0d1hpS0R2RWNRcl…
BMGL|Basel Medical Group Ltd|Price:5.660|Chg%:-0.320 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBLcnVjNno5cTZQOEhKQ1ZHdXREcDh1QzVlMER0MmxYUlg3Ri03ZUR1OW00U010dGJla2Q3TUxZUlBndGdITllYcTNsVi1aa1ZEalZXY0dDR2tKLVd1aWhjdF92VXIzWkdvb3cweEh3?oc=5" target="_blank">BMGL|Basel Medical …
Basel Medical Group Ltd (BMGL) Slides 2.77% as Stock Nears Key Support at $6.35 - Short Term Trading Ideas - po-news-eg.net
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNVmxLNWp6TWV1Wkt2MWx6WF9tUXRURUNMX3pCemxUU1hzZFhoYlNrT0VUSG5xZDNvS2dnd3VRRUFmaF9SWEFNYTNUb3dBZ3RlM19qT21MMkxIYXF1a2FJdmJXc1NhX1MwdGFMMlR5cjVqREtXZnlVTzJaMEpDX3RaOFFvRFR4eWFUeWVXOG…
Basel Medical Group (BMGL) Slides 4.5%: Key Support Level in Focus - Price Surge Stocks - dars.gov.et
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWFQ4SHhwOWY5dzJDNGpQLV95TW1WZFBRNzhhNUN6SDJBRVJ5V1F3SUFoRy1TczF0cWxQY1AwNUwydldDclk1UGttZWh1U0wtQXNreERqVVhyWW5SVTBYaENYTm13LVNDNVdxYUwxdV9yM2YyN3EzdzRhQTlJZmZrbmp0dUpzcWlMWFo5MF…
BMGL — Frequently Asked Questions
What is the current share price of Basel Medical Group Ltd (BMGL)?
As of 2026-08-05 17:25 PDT, Basel Medical Group Ltd (BMGL) trades at $5.60 on NasdaqCM. Its 52-week range is $5.26 to $26.16.
What is the market capitalisation of BMGL?
Basel Medical Group Ltd (BMGL) has a market capitalisation of $8.77M on NasdaqCM.
What is the P/E ratio of BMGL?
BMGL trades at a trailing price-to-earnings (P/E) ratio of -0.97. The industry average P/E is 25.51. Its price-to-book (P/B) ratio is 1.79.
What is the return on equity (ROE) of BMGL?
BMGL has a return on equity (ROE) of -147.37%. Its return on capital employed (ROCE) is -127.36%.
Is BMGL a good stock to buy?
This page provides a data-driven analysis of Basel Medical Group Ltd (BMGL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.